Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

Recruiting now · Not applicable

Conditions studied: Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage

In brief

Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.

Key facts

Study ID

NCT04942080

Run by

University Hospital, Angers

People needed

260

Starts

2021-10-28

Expected to finish

2030-04-28

Last updated by the study team

2026-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults (age ≥18 years),
• affiliated to the national social security system,
• with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,
• for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,
• who signed the consent to participate in the study,
• included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).

You may not qualify if…

• patient with another active hematological disease or cancer at the time of diagnosis,
• person subject to legal protection scheme or incapable of giving consent.

Where it is running

• CHU Angers — Angers, France (enrolling)
• Chu Bordeaux — Bordeaux, France (enrolling)
• Chu Brest — Brest, France (enrolling)
• Ch Cholet — Cholet, France (enrolling)
• Ch Le Mans — Le Mans, France (enrolling)
• Ch Morlaix — Morlaix, France (enrolling)
• AP-HP Henri Mondor — Paris, France (enrolling)
• Chu Poitiers — Poitiers, France (enrolling)
• Ch Quimper — Quimper, France (enrolling)
• Chu Tours — Tours, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.